)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Matinas BioPharma
Matinas BioPharma (MTNB) investor relations material
Matinas BioPharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement with Azurity Pharmaceuticals for the sale of Nanotechnologies, with the combined company to focus on GH Power's business post-closing.
Net loss for the six months ended June 30, 2026 was $3.2M, a significant improvement from $6.9M in the prior year period.
Substantial doubt exists about the ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months.
Financial highlights
Cash and cash equivalents at June 30, 2026 were $761K, down from $3.99M at year-end 2025.
Stockholders' equity declined to $1.8M at June 30, 2026 from $4.8M at December 31, 2025.
Net cash used in operating activities was $3.4M for the first half of 2026, compared to $4.0M in the prior year.
No revenue was reported; all expenses were related to R&D and G&A.
Outlook and guidance
The company does not expect to continue its historical clinical-stage activities after the business combination.
If the business combination and asset sale are not completed, significant additional funding will be required, with no assurance of availability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Matinas BioPharma
- Biotech seeks up to $150M for MAT2203 advancement amid financial and operational risks.MTNB
Registration filing - Q1 2026 net loss widened to $1.92M, cash fell to $2.4M, and delisting risk persists.MTNBQ1 2026
- Net loss fell to $10.3M in 2025, but cash runway is short without new funding or a MAT2203 deal.MTNBQ4 2025
- Registering 16.9M shares for resale post-private placement, with ongoing strategic and financial risks.MTNBRegistration Filing
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing
- Approval sought for major stock issuance, auditor ratification, and potential meeting adjournment.MTNBProxy Filing
- MAT2203 licensing advances, net loss narrows, but cash shortfall raises going concern doubts.MTNBQ2 2024
- Oral MAT2203 could transform antifungal therapy by offering safer, more flexible treatment.MTNBFireside Chat
Next Matinas BioPharma earnings date
Q3 202618 Nov, 2026
Matinas BioPharma
Next Matinas BioPharma earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Matinas BioPharma Holdings Inc. is a biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology for the oral delivery of small molecules, gene therapies, and vaccines. The company's proprietary LNC platform aims to enhance the absorption and bioavailability of drugs, particularly those used to treat infectious diseases and cardiovascular conditions. The company is headquartered in Bedminster, New Jersey, and its shares are listed on the NYSE.